Zhongsheng Pharmaceutical announced that Onradivir tablets, a class of innovative drugs independently developed by its holding subsidiary, were approved for marketing in May 2025; recently, a phase III clinical trial of the drug with the new indication “treatment of influenza A with a high risk of complications” was approved by the State Drug Administration to enroll young people and adults aged 12 and above with influenza A participants.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.